GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Other Gross PPE

Cybin (CYBN) Other Gross PPE : $0.75 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Other Gross PPE?

Cybin's Other Gross PPE for the quarter that ended in Dec. 2023 was $0.75 Mil.

Cybin's quarterly Other Gross PPE increased from Jun. 2023 ($0.49 Mil) to Sep. 2023 ($0.49 Mil) and increased from Sep. 2023 ($0.49 Mil) to Dec. 2023 ($0.75 Mil).

Cybin's annual Other Gross PPE increased from Mar. 2021 ($0.37 Mil) to Mar. 2022 ($0.38 Mil) and increased from Mar. 2022 ($0.38 Mil) to Mar. 2023 ($0.49 Mil).


Cybin Other Gross PPE Historical Data

The historical data trend for Cybin's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Other Gross PPE Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Other Gross PPE
- 0.37 0.38 0.49

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.49 0.49 0.49 0.75

Cybin Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Cybin (CYBN) Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.